PEN: Ascending Triangle detected on 2 Oct 2026

Penumbra is forming an ascending triangle pattern with modest technical quality. The stock sits at $318.00, trapped between support at $318.26 and resistance at $320.29—a narrow consolidation zone of just $2.03. Structure score of 9.0 and breakout score of 10.5 indicate a relatively weak pattern, while volume ratio of 0.91 (below the 20-day average) shows participation is below normal, suggesting uncertainty. The pattern shows minimal conviction with an overall score of 57 out of a possible 98, indicating this is a lower-confidence setup. RSI of 41 suggests neither overbought nor oversold conditions.

Boston Scientific agreed to acquire Penumbra for $14.8 billion in a cash and stock deal, pricing each share at $374. The stock currently trades at $318, representing a 15% discount to deal value, reflecting merger uncertainty. Q2 2026 revenue reached $390.0 million, up 14.9% year-over-year, with thrombectomy revenue at $259.0 million (+12.5%) and embolization/access revenue at $131.1 million (+20.0%). Net income was $34.8 million with $0.88 diluted EPS. However, Incuvate filed a patent-infringement lawsuit against Penumbra in August 2026, adding litigation risk. The company will not provide 2026 guidance due to the pending transaction.

A successful breakout would require closing above resistance at $320.29 with volume confirmation above 385,000 shares. The measured move target is $330.82, representing approximately 4% upside from resistance. The win probability of 54.11% suggests slightly better-than-coin-flip odds for the breakout direction. The pattern invalidates below support at $318.26—any close below this level signals pattern failure. However, the narrow range and weak volume conditions suggest any breakout will need sustained institutional interest to materialize. Given the pending acquisition and the $374 deal value, this pattern's outcome may be subordinate to merger completion risk.

Multiple analysts maintain Hold ratings despite positive earnings, indicating limited enthusiasm. The acquisition overhang is the dominant risk: if deal certainty diminishes, the stock could revert sharply lower from $374 deal value, negating the pattern setup entirely. Patent litigation from Incuvate filed in August 2026 introduces execution risk and potential damage liability. Volume ratio of 0.91 and below-average relative volume signal weak retail interest and potential liquidity stress on breakout attempts. Low beta of 0.15 may indicate trading is deal-driven rather than fundamental, limiting traditional technical pattern relevance. The broader market regime is bearish (-0.23 regime score) and healthcare sector regime is also bearish, providing headwinds to standalone momentum.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.